J. S. Lee

发表

International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma

Masahiro Tsuboi, Iver Petersen, Hisao Asamura, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Cancer Statistics in Korea: Incidence, Mortality and Survival in 2005

Hai-rim Shin, Sohee Park, J. S. Lee, 2009, Journal of Korean medical science.

DNA repair gene polymorphisms and benefit from gefitinib in never‐smokers with lung adenocarcinoma

Heung Tae Kim, K. Yoon, Ji-Youn Han, 2011, Cancer.

Combined effects of genetic polymorphisms in six selected genes on lung cancer susceptibility.

J. S. Lee, Mihi Yang, Yunhee Choi, 2007, Lung cancer.

Integrated pharmacogenetic prediction of irinotecan pharmacokinetics and toxicity in patients with advanced non-small cell lung cancer.

Ji-Youn Han, J. S. Lee, Hyeong-Seok Lim, 2009, Lung cancer.

Randomized Phase II study of two opposite administration sequences of irinotecan and cisplatin in patients with advanced nonsmall cell lung carcinoma

Hyae-Young Kim, Dae-Ho Lee, Ji-Youn Han, 2006, Cancer.

Initial clinical trial of oral TAC-101, a novel retinoic acid receptor-alpha selective retinoid, in patients with advanced cancer.

W. Hong, J. Marshall, N. Rizvi, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Biomarkers in aerodigestive tract chemoprevention trials

S. Lippman, R. Lotan, W. Hong, 1993 .

Randomized phase 2 study of subcutaneous amifostine versus epoetin‐α given 3 times weekly during concurrent chemotherapy and hyperfractionated radiotherapy for limited‐disease small cell lung cancer

Hyae-Young Kim, Heung Tae Kim, Dae-Ho Lee, 2008, Cancer.

Decision analysis for prophylactic cranial irradiation for patients with small-cell lung cancer.

J. Lee, R. Komaki, S. Cantor, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Association of CYP2A6 polymorphisms with S-1 plus docetaxel therapy outcomes in metastatic gastric cancer.

I. Choi, M. Kook, Young-Woo Kim, 2009, Pharmacogenomics.

Robust Association Tests for the Replication of Genome-Wide Association Studies

N. Geller, J. Joo, Ju-Hyun Park, 2015, BioMed research international.

Detection of EGFR-activating mutations from plasma DNA as a potent predictor of survival outcomes in FASTACT 2: A randomized phase III study on intercalated combination of erlotinib (E) and chemotherapy (C).

T. Mok, Yi-long Wu, B. Klughammer, 2013 .

Safety and Optimal Neuroprotection of neu2000 in acute Ischemic stroke with reCanalization: study protocol for a randomized, double-blinded, placebo-controlled, phase-II trial

Á. Chamorro, E. Kim, D. Choi, 2018, Trials.

WITHDRAWN:The Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration for Re-biopsy in Previously Treated Lung Cancer.

Hyae-Young Kim, Jong Mog Lee, Joohae Kim, 2018, Cancer research and treatment : official journal of Korean Cancer Association.

Role of positron emission tomography in pretreatment lymph node staging of uterine cervical cancer: a prospective surgicopathologic correlation study.

K. Kang, J. S. Lee, S. Seo, 2005, European journal of cancer.

Primary chemotherapy for newly diagnosed nonsmall cell lung cancer patients with synchronous brain metastases compared with whole‐brain radiotherapy administered first

Heung Tae Kim, Dae-Ho Lee, Ji-Youn Han, 2008, Cancer.

Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecan‐pharmacokinetics and clinical outcome in patients with advanced non‐small cell lung cancer

E. Shin, Yeon‐Kyeong Yoo, Heung Tae Kim, 2007, Cancer.

Prognostic value of gross tumor volume for definitive radiation therapy in patients with locoregionally recurrent non-small-cell lung cancer after surgical resection.

Moon Soo Kim, Tae Hyun Kim, Heung Tae Kim, 2013, Clinical lung cancer.

Identification of occult tumors by whole-specimen mapping in solitary papillary thyroid carcinoma.

S. Dong, J. S. Lee, Eun Kyung Lee, 2015, Endocrine-related cancer.

Unmet Needs in the Treatment of Metastatic Non-small-cell Lung Cancer

Ji-Youn Han, J. S. Lee, 2008 .

Expression of cyclooxygenase‐1 and cyclooxygenase‐2 in bronchial epithelium and nonsmall cell lung carcinoma

W. Hong, J. Kurie, J. S. Lee, 2002, Cancer.

First-iGAP: A Randomized Placebo-Controlled Phase II Study of First-line Intercalated Gefitinib and Pemetrexed-Cisplatin Chemotherapy for Never-Smoker Lung Adenocarcinoma Patients.

Hyae-Young Kim, Heung Tae Kim, Ji-Youn Han, 2020, Clinical lung cancer.

Incorporating Erlotinib or Irinotecan Plus Cisplatin into Chemoradiotherapy for Stage III Non-small Cell Lung Cancer According to EGFR Mutation Status

K. Lim, Heung Tae Kim, Ji-Youn Han, 2017, Cancer research and treatment : official journal of Korean Cancer Association.

First-Line Gefitinib Treatment for Patients with Advanced Non-small Cell Lung Cancer with Poor Performance Status

Hyae-Young Kim, Heung Tae Kim, Ji-Youn Han, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Efficacy and Safety of Cisplatin/Pemetrexed Versus Cisplatin/Gemcitabine as First-Line Treatment in East Asian Patients with Advanced Non-small Cell Lung Cancer: Results of an Exploratory Subgroup Analysis of a Phase III Trial

G. Scagliotti, Keunchil Park, Chih-Hsin Yang, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Clinical Characteristics of Malignant Pericardial Effusion Associated with Recurrence and Survival

Moon Soo Kim, Jong Mog Lee, J. Zo, 2010, Cancer research and treatment : official journal of Korean Cancer Association.

Randomized phase 2 study of irinotecan plus cisplatin versus gemcitabine plus vinorelbine as first‐line chemotherapy with second‐line crossover in patients with advanced nonsmall cell lung cancer

Hyae-Young Kim, Heung Tae Kim, Dae-Ho Lee, 2008, Cancer.

ERCC1 Expression-Based Randomized Phase II Study of Gemcitabine/Cisplatin Versus Irinotecan/Cisplatin in Patients with Advanced Non-small Cell Lung Cancer

K. Lim, Ji-Youn Han, B. Nam, 2016, Cancer research and treatment : official journal of Korean Cancer Association.

Pathway-Based Analysis Using Genome-wide Association Data from a Korean Non-Small Cell Lung Cancer Study

K. Yoon, J. S. Lee, Donghoon Lee, 2013, PloS one.

Systemic Nocardiosis Mimicking Disease Flare-up after Discontinuation of Gefitinib in a Patient with EGFR-Mutant Lung Cancer

J. S. Lee, Sang-Hyun Hwang, Mihong Choi, 2014, Tuberculosis and respiratory diseases.

ERCC1 Expression-Based Randomized Phase II Study of Gemcitabine/Cisplatin Versus Irinotecan/Cisplatin in Patients with Advanced Non-small Cell Lung Cancer

K. Lim, Ji-Youn Han, B. Nam, 2016, Cancer research and treatment : official journal of Korean Cancer Association.

Tumor marker analyses from the phase III, placebo-controlled, FASTACT-2 study of intercalated erlotinib with gemcitabine/platinum in the first-line treatment of advanced non-small-cell lung cancer.

T. Mok, Yi-long Wu, S. Thongprasert, 2016, Lung cancer.

Preschool children and their mothers are more exposed to paternal smoking at home than school children and their mothers.

M. Seong, J. S. Lee, S. Kong, 2010, Clinica chimica acta; international journal of clinical chemistry.

Sarcomatoid carcinoma of the lung. Immunohistochemieal and ultrastructural studies of 14 cases

A. Sahin, N. Ordóñez, J. S. Lee, 1992, Cancer.

BIOMARKER ANALYSES AND OVERALL SURVIVAL (OS) FROM THE RANDOMIZED, PLACEBO-CONTROLLED, PHASE 3, FASTACT-2 STUDY OF INTERCALATED ERLOTINIB WITH FIRST-LINE CHEMOTHERAPY IN ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC)

T. Mok, S. Thongprasert, B. Klughammer, 2012 .

GSTT2 promoter polymorphisms and colorectal cancer risk

Hai-rim Shin, Il-Jin Kim, J. S. Lee, 2007, BMC Cancer.

Phase II study of weekly paclitaxel and capecitabine in patients with metastatic or recurrent esophageal squamous cell carcinoma

Hyae-Young Kim, Heung Tae Kim, Ji-Youn Han, 2011, BMC Cancer.

CYP1B1, CYP1A1, MPO, and GSTP1 polymorphisms and lung cancer risk in never-smoking Korean women.

K. Yoon, J. S. Lee, B. Hwangbo, 2008, Lung cancer.

Vandetanib versus placebo in patients with advanced non-small cell lung cancer (NSCLC) after prior therapy with an EGFR tyrosine kinase inhibitor (TKI): A randomized, double-blind phase III trial (ZEPHYR).

Keunchil Park, R. Perng, J. S. Lee, 2010 .

Levels of tobacco-specific metabolites among non-smoking lung cancer cases at diagnosis: case-control findings.

Heung Tae Kim, J. S. Lee, Sang-Hyun Hwang, 2013, Asian Pacific journal of cancer prevention : APJCP.

Frequent inactivation of p16INK4a in oral premalignant lesions

S. Lippman, R. Lotan, W. Hong, 1997, Oncogene.

Reduced local recurrence of a single brain metastasis through microscopic total resection.

J. Zo, B. Nam, J. S. Lee, 2009, Journal of neurosurgery.

Effect of Accurate Staging Using Positron Emission Tomography on the Outcomes of Prophylactic Cranial Irradiation in Patients With Limited Stage Small‐Cell Lung Cancer

Heung Tae Kim, Ji-Youn Han, J. S. Lee, 2017, Clinical lung cancer.

Phase I study of paclitaxel administered by ten-day continuous infusion

S. Lippman, R. Perez-soler, J. Kurie, 1998, Investigational New Drugs.

Chemoport with a non-collapsible chamber as a replacement for an Ommaya reservoir in the treatment of leptomeningeal carcinomatosis

J. Joo, J. S. Lee, H. Yoo, 2011, Acta Neurochirurgica.

Comparisons of Effects of Biman-tang according to Administration Period in Childhood Obesity

Jae-Woo Park, J. S. Lee, Seorim Min, 2013 .

Variation in TP63 is associated with lung adenocarcinoma susceptibility in Japanese and Korean populations

Yusuke Nakamura, T. Morizono, T. Tsunoda, 2010, Nature Genetics.

Analysis of Treatment Outcomes of Intraventricular Chemotherapy in 105 Patients for Leptomeningeal Carcinomatosis from Non–Small-Cell Lung Cancer

J. Joo, Heung Tae Kim, Ji-Youn Han, 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Subcutaneous Intraventricular Reservoirs

J. Joo, Heung Tae Kim, Ji-Youn Han, 2013 .

Effects of amifostine on acute toxicity from concurrent chemotherapy and radiotherapy for inoperable non-small-cell lung cancer: report of a randomized comparative trial.

R. Herbst, C. Stevens, R. Komaki, 2004, International journal of radiation oncology, biology, physics.

Randomized Phase III Trial of Docetaxel Versus Vinorelbine or Ifosfamide in Patients With Advanced Non–Small-Cell Lung Cancer Previously Treated With Platinum-Containing Chemotherapy Regimens

M. Kris, D. Gandara, V. Miller, 2000 .

Frequent microsatellite alterations at chromosomes 9p21 and 3p14 in oral premalignant lesions and their value in cancer risk assessment

S. Lippman, W. Hong, L. Mao, 1996, Nature Medicine.

Prediction of Cancer Incidence and Mortality in Korea, 2014

J. S. Lee, K. Jung, Y. Won, 2014, Cancer research and treatment : official journal of Korean Cancer Association.

Dose-volumetric parameters for predicting severe radiation pneumonitis after three-dimensional conformal radiation therapy for lung cancer.

Tae Hyun Kim, Hyae-Young Kim, Dae-Ho Lee, 2005, Radiology.

Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin.

E. Shin, Yeon‐Kyeong Yoo, Dae-Ho Lee, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Short Arm of Chromosome 9 in Small Cell Lung Cancer Identification of Three Distinct Tumor Suppressor Loci on the Updated

Y. Sekido, J. Ro, K. Fong, 2006 .

ZD1839 (Iressa TM ) In Non-Small-Cell Lung Cancer

F. Khuri, R. Herbst, K. Pisters, 2001 .

A genome-wide association study reveals susceptibility variants for non-small cell lung cancer in the Korean population.

Yusuke Nakamura, M. Kubo, Jong Eun Lee, 2010, Human molecular genetics.

Genetic Polymorphisms in the Polycomb Group Gene EZH2 and the Risk of Lung Cancer

K. Yoon, Jaehee Park, J. S. Lee, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Genetic polymorphisms in the Rb-binding zinc finger gene RIZ and the risk of lung cancer.

H. Shin, H. Cheong, Hai-rim Shin, 2007, Carcinogenesis.

Novel polymorphisms in the SUV39H2 histone methyltransferase and the risk of lung cancer.

Il-Jin Kim, Kyong-Ah Yoon, Jong Eun Lee, 2006, Carcinogenesis.

Clinical outcome according to the level of preexisting epidermal growth factor receptor T790M mutation in patients with lung cancer harboring sensitive epidermal growth factor receptor mutations

Heung Tae Kim, Joo‐Hang Kim, Ji-Youn Han, 2014, Cancer.

First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung.

Hyae-Young Kim, J. Ahn, M. Ahn, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Dysregulated cyclin D1 expression early in head and neck tumorigenesis: in vivo evidence for an association with subsequent gene amplification

W. Hong, Xia Li, W. Hittelman, 1998, Oncogene.

Ventriculolumbar Perfusion Chemotherapy for the Treatment of Leptomeningeal Carcinomatosis: A Phase I Study With Pharmacokinetic Data

Heung Tae Kim, Ji-Youn Han, J. S. Lee, 2013, American journal of clinical oncology.

Prognostic implications of genetic variants in advanced non-small cell lung cancer: a genome-wide association study.

Kyong-Ah Yoon, Jungnam Joo, J. Joo, 2013, Carcinogenesis.

Clinical likelihood of sporadic primary EGFR T790M mutation in EGFR-mutant lung cancer.

Heung Tae Kim, J. S. Lee, T. Yun, 2015, Clinical lung cancer.

The new IASLC/ATS/ERS international multidisciplinary lung adenocarcinoma classification

J. Austin, A. Nicholson, I. Petersen, 2009 .

Randomized Phase II Study of Afatinib Plus Simvastatin Versus Afatinib Alone in Previously Treated Patients with Advanced Nonadenocarcinomatous Non-small Cell Lung Cancer

K. Lim, J. Joo, Ji-Youn Han, 2017, Cancer research and treatment : official journal of Korean Cancer Association.

A Randomized Phase II Study of Gefitinib Plus Simvastatin Versus Gefitinib Alone in Previously Treated Patients with Advanced Non–Small Cell Lung Cancer

Heung Tae Kim, Ji-Youn Han, N. Yoo, 2011, Clinical Cancer Research.

Cigarette smoking and cancer incidence risk in adult men: National Health Insurance Corporation Study.

Y. Yun, J. S. Lee, K. Jung, 2005, Cancer detection and prevention.

A phase 2 study of irinotecan, cisplatin, and simvastatin for untreated extensive‐disease small cell lung cancer

K. Lim, Heung Tae Kim, Ji-Youn Han, 2011, Cancer.

Randomized Phase II Study of Maintenance Irinotecan Therapy Versus Observation Following Induction Chemotherapy with Irinotecan and Cisplatin in Extensive Disease Small Cell Lung Cancer

K. Lim, Heung Tae Kim, Dae-Ho Lee, 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Influence of the organic anion-transporting polypeptide 1B1 (OATP1B1) polymorphisms on irinotecan-pharmacokinetics and clinical outcome of patients with advanced non-small cell lung cancer.

Hyeong-Seok Lim, E. Shin, Yeon‐Kyeong Yoo, 2008, Lung cancer.

A randomized phase II study of bortezomib and pemetrexed, in combination or alone, in patients with previously treated advanced non-small-cell lung cancer.

G. Scagliotti, Keunchil Park, F. de Marinis, 2010, Lung cancer.

Usefulness of Urinary Cotinine Test to Distinguish Smokers from Nonsmokers

Seung-Yong Jeong, Y. Yun, J. S. Lee, 2003 .

Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2011

J. S. Lee, K. Jung, Y. Won, 2014, Cancer research and treatment : official journal of Korean Cancer Association.

Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy

T. Mok, Yi-long Wu, S. Thongprasert, 2015, Clinical Cancer Research.

Phase II study of 10-ethyl-10-deaza-aminopterin (10-EdAM; CGP 30 694) for stage IIIB or IV non-small cell lung cancer

W. Hong, H. Libshitz, J. S. Lee, 1990, Investigational New Drugs.

A Phase II Study of Poziotinib in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Lung Adenocarcinoma Who Have Acquired Resistance to EGFR–Tyrosine Kinase Inhibitors

Hyae-Young Kim, Sang-We Kim, Y. Min, 2016, Cancer research and treatment : official journal of Korean Cancer Association.

Vandetanib Versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: a randomized, double-blind phase III trial (ZEPHYR).

Keunchil Park, Yuh-Min Chen, R. Perng, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comparison of clinical outcome of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations

K. Lim, Heung Tae Kim, K. Yoon, 2011, Journal of Clinical Pathology.

Early neutrophil-to-lymphocyte ratio reduction as a surrogate marker of prognosis in never smokers with advanced lung adenocarcinoma receiving gefitinib or standard chemotherapy as first-line therapy

Heung Tae Kim, Ji-Youn Han, J. S. Lee, 2012, Journal of Cancer Research and Clinical Oncology.

A Pilot Trial of Gemcitabine and Vinorelbine Plus Capecitabine in Locally Advanced or Metastatic Nonsmall Cell Lung Cancer

Seong Min Yoon, Hyae-Young Kim, Dae-Ho Lee, 2006, American journal of clinical oncology.

Phase II study of induction chemotherapy with gemcitabine and vinorelbine followed by concurrent chemoradiotherapy with oral etoposide and cisplatin in patients with inoperable stage III non-small-cell lung cancer.

Hyae-Young Kim, Dae-Ho Lee, Ji-Youn Han, 2005, International journal of radiation oncology, biology, physics.

Gefitinib as a First-Line Therapy of Advanced or Metastatic Adenocarcinoma of the Lung in Never-Smokers

Hyae-Young Kim, Dae-Ho Lee, Ji-Youn Han, 2005, Clinical Cancer Research.

Twice daily irradiation increases locoregional control in patients with medically inoperable or surgically unresectable stage II-IIIB non-small-cell lung cancer.

C. Stevens, R. Komaki, Z. Liao, 2002, International journal of radiation oncology, biology, physics.

Impact of institutional experience on survival outcome of patients undergoing combined chemoradiation therapy for inoperable non-small-cell lung cancer.

D. Ettinger, R. Komaki, W. Sause, 2002, International journal of radiation oncology, biology, physics.

Circulating Cell-Free DNA in Plasma of Never Smokers with Advanced Lung Adenocarcinoma Receiving Gefitinib or Standard Chemotherapy as First-Line Therapy

Hyae-Young Kim, Heung Tae Kim, K. Yoon, 2011, Clinical Cancer Research.

Phase II Study of Pemetrexed as a Salvage Chemotherapy for Thymidylate Synthase–Low Squamous Cell Lung Cancer

K. Lim, J. Joo, Heung Tae Kim, 2020, Cancer research and treatment : official journal of Korean Cancer Association.

Ceritinib-Induced Organizing Pneumonia in Lung Cancer: A Retrospective Analysis

Hyun-ju Lim, Heung Tae Kim, Ji-Youn Han, 2020, Targeted Oncology.

Real-World Experience of Nivolumab in Non-small Cell Lung Cancer in Korea

M. Ahn, E. Cho, Dong-Wan Kim, 2020, Cancer research and treatment : official journal of Korean Cancer Association.

Clinical significance of heterogeneity in response to retreatment with epidermal growth factor receptor tyrosine kinase inhibitors in patients with lung cancer acquiring secondary resistance to the drug.

K. Lim, Hyae-Young Kim, Heung Tae Kim, 2014, Clinical lung cancer.

Predictive Biomarkers and Personalized Medicine Circulating Cell-Free DNA in Plasma of Never Smokers with Advanced Lung Adenocarcinoma Receiving Gefitinib or Standard Chemotherapy as First-Line Therapy

Hyae-Young Kim, Heung Tae Kim, K. Yoon, 2011 .

Comparison of Epidermal Growth Factor Receptor Mutations between Metastatic Lymph Node Diagnosed by EBUS-TBNA and Primary Tumor in Non-Small Cell Lung Cancer

Moon Soo Kim, Jong Mog Lee, J. S. Lee, 2016, PloS one.

Impact of EGFR tyrosine kinase inhibitors versus chemotherapy on the development of leptomeningeal metastasis in never smokers with advanced adenocarcinoma of the lung

Hyae-Young Kim, Heung Tae Kim, Ji-Youn Han, 2013, Journal of Neuro-Oncology.

Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial.

Li Zhang, Hongming Pan, Chong-Jen Yu, 2013, The Lancet. Oncology.

Association of p53 codon 72 polymorphism and MDM2 SNP309 with clinical outcome of advanced nonsmall cell lung cancer

Dae Ho Jang, Ji-Youn Han, J. S. Lee, 2008, Cancer.

Alleviation by leucovorin of the dose-limiting toxicity of edatrexate: potential for improved therapeutic efficacy

W. Hong, J. S. Lee, W. Murphy, 2004, Cancer Chemotherapy and Pharmacology.

Genomic profile analysis of diffuse-type gastric

Yun Sung Cho, Byoung-Chul Kim, J. Bhak, 2014 .

Genomic profile analysis of diffuse-type gastric cancers

Yun Sung Cho, Byoung-Chul Kim, J. Bhak, 2014, Genome Biology.

DNA microarray analysis of the correlation between gene expression patterns and acquired resistance to 5-FU/cisplatin in gastric cancer.

Il-Jin Kim, Jae-Hyun Park, Hio Chung Kang, 2004, Biochemical and biophysical research communications.

A nomogram to predict brain metastasis as the first relapse in curatively resected non-small cell lung cancer patients.

Moon Soo Kim, Heung Tae Kim, Ji-Youn Han, 2015, Lung cancer.

Lung Cancer Screening with Low-Dose CT in Female Never Smokers: Retrospective Cohort Study with Long-term National Data Follow-up

K. Lim, Hyae-Young Kim, Jeongseon Kim, 2017, Cancer research and treatment : official journal of Korean Cancer Association.

Weekly Docetaxel in Combination With Capecitabine in Patients With Metastatic Gastric Cancer

I. Choi, Young-Woo Kim, K. Ryu, 2005, American journal of clinical oncology.

Novel polymorphisms in the SUV 39 H 2 histone methyltransferase and the risk of lung cancer

Il-Jin Kim, Kyong-Ah Yoon, Jong Eun Lee, 2006 .

Radiosensitivity Enhancement by Combined Treatment of Celecoxib and Gefitinib on Human Lung Cancer Cells

J. Zo, J. S. Park, J. S. Lee, 2006, Clinical Cancer Research.

Sequential Treatment with an Immune Checkpoint Inhibitor Followed by a Small-Molecule Targeted Agent Increases Drug-Induced Pneumonitis

Hyae-Young Kim, Heung Tae Kim, Ji-Youn Han, 2020, Cancer research and treatment : official journal of Korean Cancer Association.

Association of SUMO1 and UBC9 genotypes with tumor response in non-small-cell lung cancer treated with irinotecan-based chemotherapy

Heung Tae Kim, Ji-Youn Han, J. S. Lee, 2010, The Pharmacogenomics Journal.

Ventriculolumbar perfusion chemotherapy with methotrexate for treating leptomeningeal carcinomatosis: a Phase II Study.

Heung Tae Kim, Ji-Youn Han, J. S. Lee, 2014, The oncologist.

A phase I study of topotecan/paclitaxel alternating with etoposide/cisplatin and thoracic irradiation in patients with limited small cell lung cancer.

R. Komaki, J. Kurie, K. Pisters, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Trends in Cancer Screening Rates among Korean Men and Women: Results from the Korean National Cancer Screening Survey (KNCSS), 2004-2010

K. Choi, J. S. Lee, E. Park, 2011, Cancer research and treatment : official journal of Korean Cancer Association.

The prognostic impact of microRNA sequence polymorphisms on the recurrence of patients with completely resected non-small cell lung cancer.

K. Yoon, J. Zo, Sohee Park, 2012, The Journal of thoracic and cardiovascular surgery.

Genetic Variations Associated with Postoperative Recurrence in Stage I Non–Small Cell Lung Cancer

Kyong-Ah Yoon, J. Joo, K. Yoon, 2014, Clinical Cancer Research.

Growth rates of metastatic brain tumors in nonsmall cell lung cancer

B. Nam, J. S. Lee, H. Yoo, 2008, Cancer.

Dose-volumetric parameters of acute esophageal toxicity in patients with lung cancer treated with three-dimensional conformal radiotherapy.

Tae Hyun Kim, I. Choi, K. Shin, 2005, International journal of radiation oncology, biology, physics.

Relative and Absolute Risks of Cigarette Smoking on Major Histologic Types of Lung Cancer in Korean Men

Sang Min Park, Y. Yun, J. S. Lee, 2005, Cancer Epidemiology Biomarkers & Prevention.

The hOGG1 Ser326Cys Polymorphism Is Not Associated with Colorectal Cancer Risk

Hai-rim Shin, Il-Jin Kim, J. S. Lee, 2007, Journal of epidemiology.

A phase II study of weekly docetaxel plus capecitabine for patients with advanced nonsmall cell lung carcinoma

Dae-Ho Lee, Ji-Youn Han, J. S. Lee, 2003, Cancer.

Randomized phase II study of platinum-based chemotherapy plus controlled diet with or without metformin in patients with advanced non-small cell lung cancer.

Ji-Youn Han, J. S. Lee, S. Y. Kim, 2020, Lung cancer.

Identification of two distinct tumor-suppressor loci on the long arm of chromosome 10 in small cell lung cancer

Li Mao, Waun K Hong, W. Hong, 1998, Oncogene.

Phase II trial of recombinant IFN-α2a with etoposide/cisplatin induction and interferon/megestrol acetate maintenance in extensive small cell lung cancer

F. Khuri, F. Fossella, J. S. Lee, 1998 .

Phase II study of irinotecan plus cisplatin induction followed by concurrent twice-daily thoracic irradiation with etoposide plus cisplatin chemotherapy for limited-disease small-cell lung cancer.

Hyae-Young Kim, Dae-Ho Lee, Ji-Youn Han, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Phase II study of synchronous three-dimensional conformal boost to the gross tumor volume for patients with unresectable Stage III non-small-cell lung cancer: results of Korean Radiation Oncology Group 0301 study.

Heung Tae Kim, W. Koom, Ji-Youn Han, 2009, International journal of radiation oncology, biology, physics.

Comparison of circulating plasma DNA levels between lung cancer patients and healthy controls.

K. Yoon, Sohee Park, J. S. Lee, 2009, The Journal of molecular diagnostics : JMD.

Phase II Trial of Gemcitabine-Carboplatin-Paclitaxel as Neoadjuvant Chemotherapy for Operable Non-small Cell Lung Cancer

Chun-Ming Tsai, T. Mok, M. Lehnert, 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

The Role of Gefitinib Treatment for Korean Never-Smokers with Advanced or Metastatic Adenocarcinoma of the Lung: A Prospective Study

Hyae-Young Kim, Heung Tae Kim, Dae-Ho Lee, 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A phase II study of nintedanib in patients with relapsed small cell lung cancer.

K. Lim, Hyae-Young Kim, Ji-Youn Han, 2016, Lung cancer.

Early Prediction of Response to First-Line Therapy Using Integrated 18F-FDG PET/CT for Patients with Advanced/Metastatic Non-small Cell Lung Cancer

Hyae-Young Kim, K. Kang, Heung Tae Kim, 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A Phase II Study of Weekly Paclitaxel Plus Gemcitabine as a Second-Line Therapy in Patients with Metastatic or Recurrent Small Cell Lung Cancer

Hyae-Young Kim, Heung Tae Kim, Ji-Youn Han, 2015, Cancer research and treatment : official journal of Korean Cancer Association.

Intermediate end point markers in chemoprevention trials of lung cancer

S. Lippman, W. Hong, R. Morice, 1997 .

Efficacy and Safety of Intravenous Mesenchymal Stem Cells for Ischemic Stroke

Y. Kim, W. Chang, J. S. Lee, 2021, Neurology.

A randomized placebo-controlled phase III study of intercalated erlotinib with gemcitabine/platinum in first-line advanced non-small cell lung cancer (NSCLC): FASTACT-II.

T. Mok, Yi-long Wu, S. Thongprasert, 2012 .

Bronchial Artery and Systemic Artery Embolization in the Management of Primary Lung Cancer Patients with Hemoptysis

Hyae-Young Kim, J. Zo, J. S. Lee, 2007, Cardiovascular and Interventional Radiology.

A phase II study of sunitinib in patients with relapsed or refractory small cell lung cancer.

K. Lim, Hyae-Young Kim, Heung Tae Kim, 2013, Lung cancer.

Age dramatically impacts on the quality-adjusted time without symptoms or toxicity (Q-Twist) in locally advanced non-Small cell lung cancer (LA-NSCLC)-a radiation therapy oncology group (RTOG) analysis

R. Komaki, W. Sause, B. Movsas, 2000 .

A phase II study of dose-intensified weekly concomitant administration of cisplatin and irinotecan in chemonaive patients with extensive-disease small-cell lung cancer

Dae-Ho Lee, Ji-Youn Han, J. S. Lee, 2005, Medical oncology.

A phase II trial of docetaxel plus capecitabine in patients with previously treated non-small cell lung cancer.

Seong Min Yoon, Hyae-Young Kim, Dae-Ho Lee, 2006, Japanese journal of clinical oncology.

Gefitinib is of more benefit in chemotherapy-naive patients with good performance status and adenocarcinoma histology: retrospective analysis of 575 Korean patients.

Heung Tae Kim, Dae-Ho Lee, Ji-Youn Han, 2006, Lung cancer.

A phase II study of irinotecan plus cisplatin for patients with advanced stage IIIB or IV NSCLC previously treated with nonplatinum‐based chemotherapy

Hyae-Young Kim, Heung Tae Kim, Dae-Ho Lee, 2006, Cancer.

A Phase II study of weekly irinotecan and capecitabine in patients with previously treated non-small cell lung cancer.

Hyae-Young Kim, Dae-Ho Lee, Ji-Youn Han, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

The effect of tumor volume and its change on survival in stage III non-small cell lung cancer treated with definitive concurrent chemoradiotherapy

Tae Hyun Kim, J. Kim, Heung Tae Kim, 2014, Radiation oncology.

Randomized phase II trial of intercalated gefitinib (G) and pemetrexed/cisplatin (Pem/Cis) for never-smokers with chemo-naïve stage IIIB/IV lung adenocarcinoma (LADC).

Hyae-Young Kim, Heung Tae Kim, Ji-Youn Han, 2016 .

A phase II trial of modified weekly irinotecan and cisplatin for chemotherapy-naïve patients with metastatic or recurrent squamous cell carcinoma of the esophagus

Hyae-Young Kim, Heung Tae Kim, Dae-Ho Lee, 2007, Cancer Chemotherapy and Pharmacology.

Identification of three distinct tumor suppressor loci on the short arm of chromosome 9 in small cell lung cancer.

J. Minna, W. Hong, L. Mao, 1997, Cancer research.

Clonal genetic alterations in the lungs of current and former smokers.

J S Lee, S. Lippman, F. Khuri, 1997, Journal of the National Cancer Institute.

Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2011

J. S. Lee, K. Jung, Y. Won, 2014, Cancer research and treatment : official journal of Korean Cancer Association.

A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer.

J. Roth, R. Komaki, E. Atkinson, 1994, Journal of the National Cancer Institute.

Recursive partitioning analysis of 1999 Radiation Therapy Oncology Group (RTOG) patients with locally-advanced non-small-cell lung cancer (LA-NSCLC): identification of five groups with different survival.

W. Sause, J. Cox, R. Komaki, 2000, International journal of radiation oncology, biology, physics.

Phenotype and genotype of advanced premalignant head and neck lesions after chemopreventive therapy.

S. Lippman, W. Hong, J. Lee, 1998, Journal of the National Cancer Institute.

Paclitaxel resistance in non-small-cell lung cancer associated with beta-tubulin gene mutations.

R. Rosell, M. Monzó, Cristina Martín, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Genomic profile analysis of diffuse-type gastric cancers.

Yun Sung Cho, Byoung-Chul Kim, J. Bhak, 2014, Genome biology.

A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer.

J. Roth, E. Atkinson, F. Fossella, 1994, Journal of the National Cancer Institute.

Neoadjuvant chemotherapy in stage Illa non-small cell lung cancer LEARNING POINTS *

R. Komaki, E. Atkinson, A. Ariza, 2022 .

Clinical significance of lymphatic/vascular tumor cells (LVT) and adjuvant chemotherapy (AC) after curative resection of non-small cell lung cancer (NSCLC)

E. Choi, J. Ro, C. Suh, 2005 .

The benefit of treatment intensification is age and histology-dependent in patients with locally advanced non-small cell lung cancer (NSCLC): a quality-adjusted survival analysis of radiation therapy oncology group (RTOG) chemoradiation studies.

W. Sause, B. Movsas, J. Cox, 1999, International journal of radiation oncology, biology, physics.

C-MET overexpression as a resistance biomarker to epidermal growth factor receptor tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer.

Heung Tae Kim, Ji-Youn Han, Ji‐Young Shin, 2016 .

International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma

J. Austin, I. Petersen, V. Rusch, 2011, Journal of Thoracic Oncology.

Clinical likelihood of sporadic primary EGFR T790M mutation in EGFR-mutant lung cancer.

Heung Tae Kim, J. S. Lee, T. Yun, 2015, Clinical lung cancer.

Keunchil Park, Yuh-Min Chen, R. Perng, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer

G. Scagliotti, Keunchil Park, F. de Marinis, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Retrospective evaluation of RET biomarker status and outcome to vandetanib in four phase III randomized NSCLC trials.

R. Herbst, P. Elvin, A. Platt, 2013 .

Phase II study of weekly irinotecan plus capecitabine for chemotherapy‐naive patients with advanced nonsmall cell lung carcinoma

Hyae-Young Kim, Heung Tae Kim, Dae-Ho Lee, 2005, Cancer.

A phase 2 study of irinotecan, cisplatin, and simvastatin for untreated extensive‐disease small cell lung cancer

K. Lim, Heung Tae Kim, Ji-Youn Han, 2011, Cancer.

FAST-ACT: A phase II randomized double-blind trial of sequential erlotinib and chemotherapy as first-line treatment in patients (pts) with stage IIIB/IV non-small cell lung cancer (NSCLC)

Yi-long Wu, Yuh-Min Chen, T. Mok, 2008 .